Chronic kidney disease (CKD) is a public health epidemic that increases risk of death due to cardiovascular disease. Left ventricular hypertrophy (LVH) is an important mechanism of cardiovascular disease in individuals with CKD. Elevated levels of FGF23 have been linked to greater risks of LVH and mortality in patients with CKD, but whether these risks represent causal effects of FGF23 is unknown. Here, we report that elevated FGF23 levels are independently associated with LVH in a large, racially diverse CKD cohort. FGF23 caused pathological hypertrophy of isolated rat cardiomyocytes via FGF receptor–dependent activation of the calcineurin-NFAT signaling pathway, but this effect was independent of klotho, the coreceptor for FGF23 in the kidney and parathyroid glands. Intramyocardial or intravenous injection of FGF23 in wild-type mice resulted in LVH, and klotho-deficient mice demonstrated elevated FGF23 levels and LVH. In an established animal model of CKD, treatment with an FGF–receptor blocker attenuated LVH, although no change in blood pressure was observed. These results unveil a klotho-independent, causal role for FGF23 in the pathogenesis of LVH and suggest that chronically elevated FGF23 levels contribute directly to high rates of LVH and mortality in individuals with CKD.
Christian Faul, Ansel P. Amaral, Behzad Oskouei, Ming-Chang Hu, Alexis Sloan, Tamara Isakova, Orlando M. Gutiérrez, Robier Aguillon-Prada, Joy Lincoln, Joshua M. Hare, Peter Mundel, Azorides Morales, Julia Scialla, Michael Fischer, Elsayed Z. Soliman, Jing Chen, Alan S. Go, Sylvia E. Rosas, Lisa Nessel, Raymond R. Townsend, Harold I. Feldman, Martin St. John Sutton, Akinlolu Ojo, Crystal Gadegbeku, Giovana Seno Di Marco, Stefan Reuter, Dominik Kentrup, Klaus Tiemann, Marcus Brand, Joseph A. Hill, Orson W. Moe, Makoto Kuro-o, John W. Kusek, Martin G. Keane, Myles Wolf
Title and authors | Publication | Year |
---|---|---|
FGF23 neutralization improves secondary hyperparathyroidism and osteodystrophy parameters yet exacerbates vascular calcification in chronic kidney disease rats
Victoria Shalhoub, Edward M Shatzen, Sabrina Ward, James Davis, Jennitte Stevens, Vivian Bi, Lisa Renshaw, Nessa Hawkins, Wei Wang, Ching Chen, Mei-Mei Tsai, Russell C Cattley, Thomas J Wronski, Xuechun Xia, Xiaodong Li, Charles Henley, Michael Eschenberg, William G Richards |
Journal of Clinical Investigation | 2012 |
Fibroblast Growth Factor 23: Friend or Foe in Uremia?
Orson Moe |
Journal of Clinical Investigation | 2012 |
Metabolic acidosis increases fibroblast growth factor 23 in neonatal mouse bone
NS Krieger, CD Culbertson, K Kyker-Snowman, DA Bushinsky |
American journal of physiology. Renal physiology | 2012 |
Calcitriol, calcidiol, parathyroid hormone, and fibroblast growth factor-23 interactions in chronic kidney disease
JF de Galvao, LA Nagode, PA Schenck, DJ Chew |
Journal of Veterinary Emergency and Critical Care | 2012 |
A Comparative Transcriptome Analysis Identifying FGF23 Regulated Genes in the Kidney of a Mouse CKD Model
B Dai, V David, A Martin, J Huang, H Li, Y Jiao, W Gu, LD Quarles |
PloS one | 2012 |
The osteocyte in CKD: New concepts regarding the role of FGF23 in mineral metabolism and systemic complications
K Wesseling-Perry, H Jüppner |
Bone | 2012 |
Fibroblast growth factor 23: state of the field and future directions
N Bhattacharyya, WH Chong, RI Gafni, MT Collins |
Trends in Endocrinology & Metabolism | 2012 |
Update on fibroblast growth factor 23 in chronic kidney disease
M Wolf |
Kidney International | 2012 |
Fibroblast Growth Factor-23 Helps Explain the Biphasic Cardiovascular Effects of Vitamin D in Chronic Kidney Disease
P Hu, Q Xuan, B Hu, L Lu, J Wang, YH Qin |
International journal of biological sciences | 2012 |
FGF23 production by osteocytes
LF Bonewald, MJ Wacker |
Pediatric Nephrology | 2012 |
Fibroblast growth factor 23 and adverse clinical outcomes in chronic kidney disease:
T Isakova |
Current Opinion in Nephrology and Hypertension | 2012 |
Fibroblast growth factor 23 inhibits extrarenal synthesis of 1,25-dihydroxyvitamin D in human monocytes
J Bacchetta, JL Sea, RF Chun, TS Lisse, K Wesseling-Perry, B Gales, JS Adams, IB Salusky, M Hewison |
Journal of Bone and Mineral Research | 2012 |
FGF23 suppresses chondrocyte proliferation in the presence of soluble α-Klotho both in vitro and in vivo
M Kawai, S Kinoshita, A Kimoto, Y Hasegawa, K Miyagawa, M Yamazaki, Y Ohata, K Ozono, T Michigami |
The Journal of biological chemistry | 2012 |
Regression of Vascular Calcification in Chronic Kidney Disease - Feasible or Fantasy - a review of the clinical evidence: Regression of Vascular Calcification in Chronic Kidney Disease
O Leonard, J Spaak, D Goldsmith |
British Journal of Clinical Pharmacology | 2012 |
Cardioprotection by Klotho through downregulation of TRPC6 channels in the mouse heart
J Xie, SK Cha, SW An, M Kuro-O, L Birnbaumer, CL Huang |
Nature Communications | 2012 |
FGF23 and PTH--double agents at the heart of CKD
J Silver, M Rodriguez, E Slatopolsky |
Nephrology Dialysis Transplantation | 2012 |
Beyond mineral metabolism, is there an interplay between FGF23 and vitamin D in innate immunity?
J Bacchetta, IB Salusky, M Hewison |
Pediatric Nephrology | 2012 |
The role of FGF23 in CKD—with or without Klotho
H Komaba, M Fukagawa |
Nature Reviews Nephrology | 2012 |
Hypophosphatemia and growth
F Santos, R Fuente, N Mejia, L Mantecon, H Gil-Peña, FA Ordoñez |
Pediatric Nephrology | 2012 |
FGF23 acts directly on renal proximal tubules to induce phosphaturia through activation of the ERK1/2–SGK1 signaling pathway
O Andrukhova, U Zeitz, R Goetz, M Mohammadi, B Lanske, RG Erben |
Bone | 2012 |
Non-Systemic Drugs: A Critical Review
D Charmot |
Current pharmaceutical design | 2012 |
Bone Biomarkers Help Grading Severity of Coronary Calcifications in Non Dialysis Chronic Kidney Disease Patients
M Morena, I Jaussent, A Halkovich, AM Dupuy, AS Bargnoux, L Chenine, H Leray-Moragues, K Klouche, H Vernhet, B Canaud, JP Cristol |
PloS one | 2012 |
An update on uremic toxins
N Neirynck, R Vanholder, E Schepers, S Eloot, A Pletinck, G Glorieux |
International Urology and Nephrology | 2012 |
Phosphate is a vascular toxin
R Shroff |
Pediatric Nephrology | 2012 |
Cardiorenal syndrome: pathophysiology and potential targets for clinical management
P Hatamizadeh, GC Fonarow, MJ Budoff, S Darabian, CP Kovesdy, K Kalantar-Zadeh |
Nature Reviews Nephrology | 2012 |
Cardiovascular risk biomarkers in CKD: the inflammation link and the road less traveled
U Elewa, MD Sanchez-Niño, C Martin-Cleary, B Fernandez-Fernandez, J Egido, A Ortiz |
International Urology and Nephrology | 2012 |
Vitamin D receptor agonists increase klotho and osteopontin while decreasing aortic calcification in mice with chronic kidney disease fed a high phosphate diet
WL Lau, EM Leaf, MC Hu, MM Takeno, M Kuro-o, OW Moe, CM Giachelli |
Kidney International | 2012 |
What's new in FGF23 research?
S Fukumoto |
BoneKEy Reports | 2012 |
Daily variability in mineral metabolites in CKD and effects of dietary calcium and calcitriol
T Isakova, H Xie, A Barchi-Chung, K Smith, N Sowden, M Epstein, G Collerone, L Keating, H Jüppner, M Wolf |
Clinical journal of the American Society of Nephrology : CJASN | 2012 |
Mineral metabolites and CKD progression in African Americans
JJ Scialla, BC Astor, T Isakova, H Xie, LJ Appel, M Wolf |
Journal of the American Society of Nephrology : JASN | 2012 |
Effects of phosphate binders in moderate CKD
GA Block, DC Wheeler, MS Persky, B Kestenbaum, M Ketteler, DM Spiegel, MA Allison, J Asplin, G Smits, AN Hoofnagle, L Kooienga, R Thadhani, M Mannstadt, M Wolf, GM Chertow |
Journal of the American Society of Nephrology : JASN | 2012 |
FGF-23 and the progression of coronary arterial calcification in patients new to dialysis
AM Khan, JA Chirinos, H Litt, W Yang, SE Rosas |
Clinical journal of the American Society of Nephrology : CJASN | 2012 |
Fibroblast growth factor 23, high-sensitivity cardiac troponin, and left ventricular hypertrophy in CKD
K Smith, C deFilippi, T Isakova, OM Gutiérrez, K Laliberte, S Seliger, W Kelley, SH Duh, M Hise, R Christenson, M Wolf, J Januzzi |
American journal of kidney diseases : the official journal of the National Kidney Foundation | 2012 |
The emerging role of Klotho in clinical nephrology
MC Hu, M Kuro-o, OW Moe |
Nephrology Dialysis Transplantation | 2012 |
Fibroblast growth factor-23 and death, heart failure, and cardiovascular events in community-living individuals: CHS (Cardiovascular Health Study)
JH Ix, R Katz, BR Kestenbaum, IH de Boer, M Chonchol, KJ Mukamal, D Rifkin, DS Siscovick, MJ Sarnak, MG Shlipak |
Journal of the American College of Cardiology | 2012 |
FGF-23 levels in patients with AKI and risk of adverse outcomes
DE Leaf, M Wolf, SS Waikar, H Chase, M Christov, S Cremers, L Stern |
Clinical journal of the American Society of Nephrology : CJASN | 2012 |
FGF23, albuminuria, and disease progression in patients with chronic IgA nephropathy
S Lundberg, AR Qureshi, S Olivecrona, I Gunnarsson, SH Jacobson, TE Larsson |
Clinical journal of the American Society of Nephrology : CJASN | 2012 |
Npt2b Deletion Attenuates Hyperphosphatemia Associated with CKD
SC Schiavi, W Tang, C Bracken, SP OBrien, W Song, J Boulanger, S Ryan, L Phillips, S Liu, C Arbeeny, S Ledbetter, Y Sabbagh |
Journal of the American Society of Nephrology : JASN | 2012 |
Associations between Kidney Function and Subclinical Cardiac Abnormalities in CKD
M Park, C Hsu, Y Li, RK Mishra, M Keane, SE Rosas, D Dries, D Xie, J Chen, J He, A Anderson, AS Go, MG Shlipak |
Journal of the American Society of Nephrology : JASN | 2012 |
The Association of Parathyroid Hormone with ESRD and Pre-ESRD Mortality in the Kidney Early Evaluation Program
G Saab, AS Bomback, SI McFarlane, S Li, SC Chen, PA McCullough, A Whaley-Connell |
The Journal of clinical endocrinology and metabolism | 2012 |
Fibroblast Growth Factor 23 and Inflammation in CKD
JM Mendoza, T Isakova, AC Ricardo, H Xie, SD Navaneethan, AH Anderson, LA Bazzano, D Xie, M Kretzler, L Nessel, LL Hamm, L Negrea, MB Leonard, D Raj, M Wolf |
Clinical journal of the American Society of Nephrology : CJASN | 2012 |
Fibroblast growth factor 23 is associated with proteinuria and smoking in chronic kidney disease: An analysis of the MASTERPLAN cohort
Vervloet MG, van Zuilen AD, Heijboer AC, ter Wee PM, Bots ML, Blankestijn PJ, Wetzels JF |
BMC Nephrology | 2012 |
Fibroblast growth factor 23 and left ventricular hypertrophy in children on dialysis.
Seeherunvong W, Abitbol CL, Chandar J, Rusconi P, Zilleruelo GE, Freundlich M |
Pediatric nephrology (Berlin, Germany) | 2012 |